Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy

Asishana A. Osho, Christopher J. Azzoli, Sara Pai, Mari Mino-Kenudson, William C. Faquin, Tiffany G. Huynh, Michael Lanuti, Douglas J. Mathisen, Ashok Muniappan

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Immune checkpoint inhibitors are emerging as therapeutic options for oncology patients in whom conventional treatment regimens have failed. These immunotherapies counteract tumor-induced tolerance and have been shown to be effective in thoracic malignancies, including non-small cell lung cancer (NSCLC). This report highlights the successful use of nivolumab—an immunotherapeutic agent that binds to proteins involved in T-cell proliferation—for the management of recurrent tracheal squamous cell cancer after exhaustion of conventional surgical, chemotherapeutic, and radiation therapy options. Observations provide a strong indication of the potential value of checkpoint inhibitors for managing a wide array of thoracic malignancies.

Original languageEnglish (US)
Pages (from-to)e123-e125
JournalAnnals of Thoracic Surgery
Issue number2
StatePublished - Feb 1 2017

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy'. Together they form a unique fingerprint.

Cite this